Table 3 from A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies

Table 3 from A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies

<p>Most common TEAEs (≥10% of the population) by preferred term.</p>

Guardat en:
Dades bibliogràfiques
Autor principal: Dejan Juric (15126249) (author)
Altres autors: Daniel Anderson (22644919) (author), Afshin Dowlati (15092092) (author), Jordi Rodon (15047721) (author), Iwona Lugowska (19135437) (author), Sławomir Mańdziuk (22644922) (author), Yuqin Song (15056930) (author), Feng Jung Sherida H. Woei-A-Jin (22644925) (author), Marc André (22644928) (author), Joanna Góra Tybor (22644931) (author), José-Ángel Hernández-Rivas (15050828) (author), Razelle Kurzrock (13559744) (author), Armando López-Guillermo (15028145) (author), David Schröder (22644934) (author), Rafal Stec (22644937) (author), Allison Berger (15134507) (author), Bo Chao (22644940) (author), Aleksander Chudnovsky (22644943) (author), John P. Gibbs (22644946) (author), Tao Long (22644949) (author), Dina Stroopinsky (16732851) (author), Qi Dong (22644952) (author), Anthony J. Olszanski (15031292) (author)
Publicat: 2025
Matèries:
Cancer
Immuno-oncology
Clinical Research and Trials
Clinical Trial Results
Phase II clinical trials
Combination Immunotherapy
Immunology
Immune responses to cancer
Phase I Clinical Trials
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars